Composition
Lyophilized fraction (live attenuated):

Canine Distemper virus, strain CDV Bio 11/A, min. 103.1 CPI50* - max. 105.1 CPI50*
Canine Adenovirus type 2, strain CAV-2-Bio 13, min. 103.6 CPI50* - max. 105.3 CPI50*
Canine Parvovirus type 2b, strain CPV-2b-Bio 12/B, min. 104.3 CPI50* - max. 106.6 CPI50*
Canine Parainfluenza virus, strain CPiV-Bio 15, min. 103.1 CPD50* - max. 105.1 CPD50*
*CPD – cytopathic dose.

Liquid fraction (inactivated):

Leptospira interrogans bacteria, serogroup Icterohaemorrhagiae, serovar Icterohaemorrhagiae, strain MSLB 1089 GMT** ≥ 1:51 IHFD ***
Leptospira interrogans bacteria, serogroup Canicola, serovar Canicola, strain MSLB 1090 GMT** ≥ 1:51 IHFD ***
Leptospira kirschneri bacteria, serogroup Grippotyphosa, serovar Grippotyphosa, strain MSLB 1091 GMT** ≥ 1:40 IHFD ***
Leptospira interrogans bacteria, serogroup Australis, serovar Bratislava, strain MSLB 1088 GMT** ≥ 1:51
** geometric mean of titers
*** above the limit of the linear range

Pharmacological properties
Immunity is developed 3 weeks after the first vaccination for CDV, CAV-1, CAV-2, CPV and 3 weeks after the completion of the first course for CPiV and 4 weeks after the completion of the first course for Leptospira components.

Duration of immunity: for at least 1 year after primary vaccination for all components of DHPPi/L4.

Indications for use
The vaccine is intended for active immunization of dogs aged 6 weeks and older:

to prevent mortality and clinical signs caused by canine distemper virus;
to prevent mortality and clinical signs caused by canine adenovirus type 1;
to prevent clinical signs and reduce virus shedding caused by canine adenovirus type 2;
to prevent clinical signs, leukopenia and virus shedding caused by canine parvovirus;
to prevent clinical symptoms and reduce virus shedding caused by canine parainfluenza virus;
to prevent clinical symptoms, virus shedding and urinary excretion caused by serovars of Leptospira bratislava, canicola, grippotyphosa and icterohaemorrhagiae.
Method of administration and dosage
Dilute one vial of lyophilisate under aseptic conditions using the contents of the vial with solvent.

Mix thoroughly and immediately administer the entire contents of the vial (1 ml) subcutaneously. Do not use chemically sterilized syringes or needles as this may affect the effectiveness of the vaccine.

Primary vaccination schedule:

2 doses of Biokan Novel DHPPi/L4 are administered separately after 3-4 weeks, starting from the age of 6 weeks and older. If protection against rabies is required, the second dose can be administered together with the compatible vaccine Biokan Novel DHPPi/L4R, provided that the second dose is administered to the animal at least 12 weeks of age and the vaccination schedule is designed accordingly (see Biokan Novel DHPPi/L4R Vaccine Specifications).

Revaccination schedule:

One dose of Biokan Novel DHPPi/L4 is administered once every three years. To protect against parainfluenza and leptospira bacteria, annual revaccination is required, so if necessary, one dose of the compatible vaccine Biokan Novel Pi/L4 can be administered annually.

Storage conditions
Store and transport in a refrigerator at 2 °C – 8 °C. Do not freeze.

Shelf life
24 months. Use immediately after dilution according to the specifications.